CELL INTELLIGENCE · 肿瘤细胞治疗研究

非典型 IκB 因子 IκBδ 增强实体瘤中 CD8 T 细胞的积聚与效应功能

The atypical IκB factor IκBδ enhances CD8 T cell accumulation and effector functions in solid tumors.

转移性上皮癌来源的 TIL（肿瘤浸润淋巴细胞）识别自体肿瘤类器官与临床疗效的相关性

Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical respon

转移性上皮癌患者中，TIL 对自体肿瘤类器官的反应性似乎与客观临床缓解相关。

靶向 T 细胞用于肿瘤治疗：当前临床策略与挑战

Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges.

紧密结合的 T 细胞簇：一类新型高效效应肿瘤杀伤细胞

Tightly bound T-cell clusters: A new class of hyper-effector tumor killers.

算法引导的个体化 T 细胞治疗：机器学习开启下一代 TCR 工程化免疫治疗

Algorithm guided personalized T cell therapy: machine learning unlocks next generation TCR engineered immunotherapy.

RELB 重编程耗竭的 TIL（肿瘤浸润淋巴细胞）以改善过继细胞治疗

RELB Reprograms Exhausted Tumor-Infiltrating Lymphocytes for Improved Adoptive Cell Therapy.

顺流而行：循环肿瘤反应性淋巴细胞涌入肿瘤治疗

Going with the Flow: Circulating Tumor-Reactive Lymphocytes Stream into Cancer Therapy.

TIL（肿瘤浸润淋巴细胞）治疗格局：前景与挑战

Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges.

自体细胞基因治疗中有意为之的异质性：首次人体试验的策略考量

Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials.

儿童恶性实体瘤 TIL（肿瘤浸润淋巴细胞）与骨髓浸润淋巴细胞的扩增

Expansion of tumor-infiltrating and marrow-infiltrating lymphocytes from pediatric malignant solid tumors.

来自儿童实体瘤的 TIL 和 MIL 扩增成功，包括全规模扩增过程。这些数据支持在儿童人群中转化为 ACT-TIL 治疗策略，因此计划在儿童高危实体瘤中开展 ACT-TIL 的 I 期试验。